Category Archives: Medizone International, Inc.

Medizone International Announces Agreement Retaining EMA Partners as Advisor and Investment Bank

KALAMAZOO, MICH. March 1, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Company has entered into a definitive agreement with EMA Partners retaining them as the Company’s advisor for financing and investment banking matters.

In late 2016, AsepticSure was cleared by the US Environmental Protection Agency for entry into the United States market.  The Company has been preparing for entry into a significant market that has a growing need for effective technologies that are capable of breaking the hospital acquired infection cycle.

“We are very pleased to announce that Medizone International has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies,” said David Esposito, Chairman and CEO of Medizone International. “As our team has completed several key milestones in the development of AsepticSure, we are preparing to scale our commercial operations in the United States and beyond.  We look forward to EMA Partners helping us realize the full potential of our business.”

“EMA Partners looks forward to working with the seasoned management team and board at Medizone to explore strategic options  to scale the business and to develop strategic partnerships with a broad range of industry players,” said Andy Raeder, founding partner of EMA Partners. “We believe the AsepticSure technology has the potential to significantly impact the large unmet need of reducing hospital acquired infections.  In addition, we see a large number of other compelling areas where this technology could be deployed to increase value creation for the Company.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections.  The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the company is now prepared to expand into the U.S. market.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the US and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 (269) 202-5020

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

About EMA Partners, LLC

EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services.

We apply a process and perspective well suited to middle market clients across all geographies. With a professional staff of advisors from a variety of business disciplines, we are able to provide the strategy, analytics, marketing and transactional work to meet our clients’ goals across industry verticals. This expertise is reflected in the wide range of transactions EMA has handled, ranging from outright sale of traditional industrial companies to licensing of sophisticated pre-revenue intellectual property.

Our focus has always been on the middle market, and on understanding client companies’ objectives and strengths, communicating those strengths to prospective buyers or partners, and structuring transactions in a manner that maximizes value for our clients.

For more information, visit www.emapartners.com.  Securities -related services provided through Burch & Company, Inc., member FINRA/SIPC.

Medizone International announces the appointment of a new Chairman and Interim CEO

San Francisco, CA. February 27, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today the appointment of David A. Esposito as Chairman of the Board and interim Chief Executive Officer.

David A. Esposito: Chairman of the Board and interim Chief Executive Officer

Effective March 1, 2017, Edwin Marshall, current Chairman and CEO, will step down from leadership of the company and will become an advisor to the Chairman through this period of transition.

“It has been an honor to lead Medizone International for the last 20 years,” commented Ed. “As we continue to position the Company as an increasingly commercially focused organization, we are very pleased to have David become our Chairman and interim CEO.  David has been an active Director of the Company since 2014 and given his leadership experience and knowledge of our business, we are confident in his ability to lead the organization through this transition into greater commercial success.”

In late 2016, AsepticSure was cleared by the US Environmental Protection Agency for entry into the United States market.  The Company has been preparing for a significant entry into the market given the growing need for effective technologies that are capable of breaking the hospital acquired infection cycle.

“On behalf of our employees, the board, and shareholders, I want to thank Ed for his leadership and commitment to the Company.  It has been Ed’s leadership and perseverance over the years that has positioned us for commercial success at this time,” commented David Esposito.  “I look forward to leading the Company through this transition as we build our commercial team to launch AsepticSure in the US and other key markets.  I would also like to recognize the effort and commitment of Dr. Michael Shannon, President and Director of Medical Affairs.  Dr. Shannon will play a critical role as we translate the clinical utility of AsepticSure into commercial success.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

The company will hold a conference call on Thursday, March 2, 2017 at 10:00 AM EST to discuss the transition and the commercial strategy moving forward.  Call in details and presentation materials will be made available on the company’s website prior to the call (www.medizoneint.com).  Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections.  The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the company is now prepared to expand into the U.S. market.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the US and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 415 331-0202

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

AsepticSure Hospital Disinfection System Expands North American Patent Coverage

San Francisco, California, December 12, 2016 – Medizone International, Inc. (The Company) (OTCQB:MZEI)  Following its recently announced EPA approval to enter the US market with its WHO Award winning and peer reviewed AsepticSure® Hospital Disinfection Technology,  the Company today announces Mexico has agreed to grant  a patent for its HEALTHCARE FACILITY DISINFECTING PROCESS AND SYSTEM WITH OXYGEN/OZONE MIXTURE.  This patent essentially conformed with the claims to those previously granted for the European Union. Countries that have now granted coverage for this revolutionary hospital disinfection technology include Canada, the United States, Mexico, China, Singapore, The United Kingdom, France and Germany with additional applications pending and processing.

Additional patent grants for BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN PEROXIDE have been granted by the United States, The United Kingdom, France and Germany.

A patent covering SPORTS EQUIPMENT AND FACILITY DISINFECTION has been granted in the United States and a Notice of Allowance received for Canada.

Medizone’s Chairman of the Board and CEO Edwin Marshall commented, “developing and proving a room disinfection system that consistently achieves 100% kill of all vegetative and spore forming bacteria as well as viral pathogens throughout the entire space being disinfected utilizing a ‘green’ technology has proven to be a considerable journey.  Management is excited about our US market entry and is pleased that International patent authorities continue to recognize the unique nature of this science and continue to grant the company patent protection for what is sure to be greatly expanding commercial opportunity as we move into 2017.”

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:

http://www.medizoneint.com
Email: [email protected]

 

AsepticSure Hospital Disinfection System Achieves EPA Approval For US Market Entry

screen-shot-2016-11-18-at-10-08-25-amSan Francisco, California, November 21, 2016 – Medizone International, Inc. (The Company) (OTCQB: MZEI) is pleased to announce that its unprecedented hospital room disinfection technology, AsepticSure®, has been given a green light for US market entry by the United States Environmental Protection Agency (EPA).

In August, Medizone announced that Cogmedix Inc., the Company’s manufacturing partner, had obtained EPA company and establishment numbers to serve as a manufacturer for the AsepticSure System. Cogmedix already held FDA medical device manufacturing status. That EPA Registration allows Cogmedix to ship AsepticSure systems to hospitals and other users in the United States. Today, we are pleased to announce that EPA has granted a Registration number for the AsepticSure specific hydrogen peroxide catalyst used in the system. The AsepticSure Oxidative Catalyst is EPA approved for use in hospitals, clinics, food industry, sporting venues, and hotels to disinfect hard, non-porous surfaces at a 1.4% concentration.

Following the Christmas holiday period, Medizone anticipates entering into a brief trial/demonstration period in a major US hospital to confirm the disinfection results previously achieved in Canada are easily repeatable.

The Company is very optimistic that EPA approval for US market entry signals a turning point for our commercial development program as we move into 2017.`

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

 

 

Medizone International, Manufacturer of AsepticSure, Closes Additional Investment

San Francisco, CA October 27, 2016. Medizone International, Inc. (The Company) (OTCQB: MZEI) manufacturers of the un-paralleled AsepticSure® Hospital Disinfection System, announces its South American distribution partner and investment group GYD S.A. operating in South America under the name BioAsepsisCorp., have completed a second investment of $1 million dollars. In November of 2015 GYD invested an initial $1 million dollars for Medizone stock with a one-year lock up. Warrants were issued for the purchase of additional shares under that agreement. The warrants have now been exercised to complete the second million-dollar investment in the Company by GYD S.A.

GYD currently holds AsepticSure distribution and service rights for Chile where they have recently achieved regulatory approval and are now commencing operations. Additional countries GYD holds rights to and expects to expand service into as regulatory approvals are achieved include Peru, Colombia, Brazil and Argentina.

Argentina is a new addition to the original distribution agreement. GYD also obtained additional warrants to purchase a third one-million dollars of Company stock, restricted under SEC Rule 144. The newly issued warrants may not be exercised prior to January 31, 2017 and have a one-year window to exercise from that date, with an expiration of January 30, 2018. Additional details of the investment may be found in the Company’s filing on SEC Form 8K.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

Medizone Progress Report

South American and US milestone regulatory events achieved
Additional patents granted
Shareholder Meeting delay due to minority shareholder proxy proposals

 

IMG_1778

August 25, 2016

Dear Shareholders,
I would like shareholders to know that management with support from our entire Board of Directors has been working diligently and faithfully to achieve the final steps necessary to see Medizone’s AsepticSure® system achieve not only regulatory approval, but successful US market acceptance.

Regulatory Approvals

Our distribution partners in South America, GYD, S.A. have recently confirmed they have now achieved ISP regulatory approval for AsepticSure into Chile, their first country of entry in S.A. ISP is the Chilean equivalent to EPA. Of the three initial systems purchased by the distributor, two are in their possession and the third is scheduled to be shipped the end of this week.

In the US, the EPA approval process has also been progressing. Cogmedix, Medizone International’s contract manufacturing partner, has obtained EPA company and establishment numbers to serve as a manufacturer for the AsepticSure delivery systems. Cogmedix already held FDA medical device manufacturing status. These numbers allow EPA to track the AsepticSure delivery system from the manufacturer to the user facility and allow Cogmedix to ship AsepticSure systems directly to hospitals in the US. This is an important step closer to market entry in the US.

Medizone’s hydrogen peroxide supplier also has an EPA registration that allows them to ship the product to users.

IMG_1780These recently achieved milestone events signal the beginning of US market entry for AsepticSure. In-hospital trials designed to replicate the success AsepticSure obtained at Trenton Memorial Hospital and Bellville General Hospital in eliminating new HAI cases for significant periods of time from AsepticSure disinfected Isolation rooms, will signal the beginning of what we believe will prove to be the successful commercial ascendance of AsepticSure in the United States. The vastly superior efficacy of AsepticSure over any competing technology, demonstrated in a highly prestigious US hospital, should signal a commercial turning point for AsepticSure leading to product acceptance and profitability for Medizone International.

 

EU Patents

On the patent front, the Company also continues its history of success. The EU patent office has granted our Health Care Patent Application. The Company is now registering coverage under the EU treaty for Germany, France and the United Kingdom. This EU patent grant follows the recent issuance of patent coverage in the EU for our bio-terrorism counter measures application, which has been registered in the same countries.

 

Annual General Meeting of Shareholders

As disclosed by the Company in its current report on Form 8-K as filed with the SEC on August 19, 2016, the Company has moved the scheduled date of its Annual Meeting of Shareholders from September 15th to December 15th.

The Board has established December 15, 2016 as the new date for the Annual Meeting, and established September 30, 2016 as the record date for stockholders entitled to notice of and to vote at the meeting.

The decision to postpone the Annual Meeting follows receipt by the Company of certain stockholder requests to include additional proposals for vote at the meeting. The stockholder proposals were received by the Company after the filing of the Company’s preliminary proxy materials with the SEC, and just prior to the mailing of the Company’s Notice of the Annual Meeting for September 15, 2016.

Pursuant to regulations of the SEC, the Company is corresponding with the stockholder proponents, and with the SEC, regarding the proposals, including with respect to issues of legality of the proposals and the Company’s alternatives for inclusion, exclusion, or revision of the proposals. In light of the proposals received, the postponement of the Annual Meeting is necessary to ensure the Company can meet applicable meeting notice deadlines and allow the Board and the proponents adequate time to evaluate the proposals and correspond with the SEC. While the Company considers the delay caused by the stockholder proposal issues unfortunate, the Company expects to be in a position to file, and mail or post to the Internet, updated proxy materials for the benefit of all Company stockholders, as required, for the December 15, 2016 meeting date.

The Company’s proxy statement filed with the SEC included a request to increase the authorized common stock vault from 395M authorized to 500M authorized in order to be assured there are shares available to secure the capital funding required to complete US market entry, initiate an increase in production and see AsepticSure through as not only the finest room disinfection system in the world, but one that is commercially profitable. Although the meeting originally scheduled on September 15 to consider that proposal has been postponed to December 15, 2016, the Company anticipates that the same proposal to increase its shares of common stock will remain in the proxy materials to be circulated for the December 15 meeting.

Under the business corporation statues of the State of Nevada applicable to the Company, the Company must obtain greater than 50% approval of all issued and outstanding shares in order to amend its Articles of Incorporation to increase the vault. The ability of the Company to fund operations and increase production is considered vital by our management team and Board of Directors. Without an increase in available shares to achieve the necessary funding to achieve these goals, the Company’s options become extremely limited. When a new proxy statement is circulated to the Company’s shareholders in connection with the December 15th meeting, it will still contain this Company proposal for an increase in share authorization to enable the adequate funding of the Company through full commercialization. We strongly urge shareholders to support this increase.

Best regards,

Edwin G. Marshall
Chairman of the Board
Chief Executive Officer

 

This letter contains certain forward-looking statements representing our expectations or beliefs regarding our company. These forward-looking statements include, but are not limited to, statements regarding our business, anticipated financial or operational results and objectives. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” anticipate,” “intend,” “could,” “estimate,” “might,” or “continue” or the negative or other variations thereof are intended to identify forward-looking statements. These statements, by their nature, involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Medizone International Selects Cogmedix as Medical Device Manufacturing Services Provider

Worcester, Massachusetts, July 19, 2016: Cogmedix, a wholly owned subsidiary of Coghlin Companies Inc., established in 1885, is proud to announce that Medizone International, Inc., (OTCQB: MZEI) has selected Cogmedix as their turnkey medical device manufacturing services provider for the AsepticSure® Generation III hospital disinfection system.

This partnership is the culmination of months of collaboration. Medizone Chairman and CEO, Edwin Marshall, was elated with this milestone and stated, “In Cogmedix we have contracted with a seasoned FDA medical device manufacturer with a depth of supply chain resources and the expertise to ensure the highest quality product is delivered, while also carefully controlling manufacturing costs. We’re convinced Cogmedix will enable us to meet significant increases in product demand as we enter the US market and also serve manufacturing requirements for international markets as AsepticSure® puts an end to environmentally caused hospital-acquired infection worldwide.”

Cogmedix Executive Vice President and General Manager, Matt Giza, shared Marshall’s enthusiasm. “Cogmedix is very excited to be a part of the impact AsepticSure® will have across the globe. The need for this technology extends well beyond hospitals. We are thrilled to be a key part of its commercialization.”

Units manufactured by Cogmedix will meet the growing demand for greater than 6-log (>99.9999%) disinfection in hospital rooms and other critical infrastructure across the globe.

The AsepticSure® process demonstrates a previously unobtainable level of hospital room disinfection within normal workflows while demonstrating immediate and dramatic reductions in new hospital- associated infection rates. AsepticSure® is the only hospital disinfection system that can guarantee a kill of infective pathogens, both bacterial and viral, of greater than 6-log (>99.9999%) throughout the entire room, and can independently verify it using the same FDA recommended testing products used to confirm surgical instrument sterilization in autoclaves.

About Cogmedix

Screen Shot 2016-07-19 at 9.31.47 AMCogmedix is a team of talented Caring Associates that brings OEM medical technology to life. Providing turnkey medical device manufacturing services to a broad range of medical and dental OEMs, Cogmedix delivers high-quality products to market with compliance, competence, and commitment. Cogmedix provides a high level of flexibility in product launch and demand management and aligns itself with innovative companies that maintain similarly high standards in honesty and integrity. Cogmedix is a subsidiary of Coghlin Companies, Inc., a privately held concept-to-commercialization firm spanning four generations. Visit Cogmedix and sign up for the e-Newsletter at www.cogmedix.com.

About Medizone

Medizone International, Inc. (OTCQB: MZEI) is a provider of patented low dose ozone based disinfection systems. The AsepticSure® hospital disinfection system, which is used in disinfecting hospital isolation rooms, surgical suites, emergency rooms, and intensive care units, as well as other enclosed spaces, such as gym locker rooms, laboratories, and veterinary clinics, establishes a new gold standard in disinfection technology by completely eliminating infective pathogens from the entire space treated. By eliminating the reservoir of infective pathogen, the treated space then remains safe until another infective pathogen is reintroduced from the outside. This breaks the chain of reinfection that hospitals globally continue to suffer through today. AsepticSure greatly reduces operational costs through the savings associated with treating far fewer HAIs. Medizone was founded in New York in 1986 and is now based in Sausalito, California. www.medizoneint.com

AsepticSure’s South American Distributor Places Order

San Francisco, California, June 20, 2016: Medizone International, Inc. (OTCQB: MZEI). GYD S.A., Medizone’s exclusive distributor for our AsepticSure® hospital disinfection system in Chile, Brazil, Colombia and Peru, intends to offer both a service model and sales model for AsepticSure distribution. They are leading the regulatory approval process in their Territory. Exclusive distribution rights will be expanded to other countries in South America on a country-by-country basis as GYD S.A. achieves regulatory approvals and establishes channels of distribution.

With regulatory approval progressing, GYD S.A. has placed an initial order for the first three Generation III AsepticSure systems. Delivery is scheduled for early July.

While the roll out of AsepticSure distribution throughout South America will be gradual, the principals of GYD S.A. have been successful twice before using the same business model in establishing distribution channels throughout the continent. Given the acute need to address major hospital based infection issues on the continent, including evidence of super bugs in Rio with the up-coming Olympic Games, the ability to greatly reduce these infection threats in the health care community is gaining attention. Medizone believes GYD S.A.’s proven business model will be successful again.

Only AsepticSure disinfection technology achieves a greater than 6-log (> 99.9999%) kill of all infective pathogensviral or bacterialthroughout the entire room. That is the same FDA standard of disinfection used to sterilize medical instruments in an autoclave. Once a room is disinfected with AsepticSure’s ‘green’ technology, it will remain safe until a new pathogen is introduced from the outside. Medizone has proven that unless 100% of infective pathogens are eliminated from the disinfected space, regrowth will occur and new infections become likely. No other disinfection technology has proven capable of eliminating the source of environmentally caused infections completely; AsepticSure does so with every room cleaning.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

AsepticSure Receives EU Patent Approval For its Bio-Terrorism Counter Measures Application

San Francisco, California, June 13, 2016 – Medizone International, Inc. (OTCQB: MZEI) is pleased to announce that its unprecedented room disinfection technology, AsepticSure®, has been granted patent protection by the European Union Patent and Trademark Office (EU) for its patent application Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide. The European Patent Office awarded patent number 252583B to this application, which provides a government counter measures response to a biological attack.

Medizone already has a significant number of applications granted for its disinfection technology for health care and sports facility disinfection. To date, AsepticSure has demonstrated a greater than 6-log kill (>99.9999% kill) against all bacterial and viral pathogens it has been tested against. This EU patent grant expands on the previously awarded bio-terrorism patent protection as awarded in the United States and Canada. With this EU patent, Medizone secures patent protection in the United Kingdom, Germany and France.

Recently, Acinetobacter baumannii, another highly infective pathogen of concern to certain US government interests as well as the government of South Africa, has been defeated by AsepticSure. To date, our AsepticSure technology has defeated every infective pathogen – viral or bacterial – that it has been tested against. Eliminating all infective pathogens from a disinfected space eliminates the infective reservoir, thus rendering the treated space harmless and safe.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

AsepticSure Research and Awards

mzei-logo-500w

asepticsure-header

–   a summary   –

AsepticSure® Research and Awards

 

 

In-print December 2010

Peer reviewed by The American Journal of Infection Control

Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces

Methods: Ozone gas at 50-500 ppm was combined with 3% hydrogen peroxide vapor in a test chamber and upscaled in rooms measuring 82 m3 and 90 m3 in area. Test organisms included methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Escherichia coli, Pseudomonas aeruginosa, Clostridium difficile, and Bacillus subtilis spores dried onto steel discs or cotton gauze pads.

 

Results: The combination of 80-ppm ozone with 1% hydrogen peroxide vapor achieved a very high level of disinfection, with a 6 log10 reduction in the bacteria and spores tested on steel discs and MRSA tested on cotton gauze during a 30- to 90-minute exposure. The entire system was scalable such that it achieved the same high level of disinfection in both the 81-m3 and 90-m3 rooms in 60-90 minutes.

 

Dick Zoutman, MD, FRCPC, Michael Shannon, MD. MSc and Arkady Mandel, MD, PhD

 

 

 

 

July 7, 2011

AsepticSure™ Hospital Disinfection System Wins International Acclaim from World Health Organization

Medizone International’s AsepticSure™ hospital disinfection system receives innovation award at the World Health Organization First International Conference on Prevention and Infection Control (ICPIC)

– Medizone International, Inc. (OTCBB:MZEI) (OTCQB:MZEI)  proudly announces that its flagship disinfection technology, AsepticSure™, has won a prestigious international award for innovation. The award was received in a competition recently held at the World Health Organization’s first International Conference on Prevention and Infection Control (ICPIC) in Geneva, Switzerland.

http://www.medizoneint.com/investor-relations/press-releases-2011/asepticsure-hospital-disinfection-system-wins-international-acclaim-world-health-organization/

 

Dick Zoutman, MD, FRCPC

 

 

 

 

 

Halifax May 2014

Canadian Infection Prevention And Control conference
(IPAC-2014
)

 Screenshot 2015-06-29 15.08.06

Queen’s University Professor Emeritus Dick Zoutman, MD, FRCPC by Poster Presentation reported on a MRSA outbreak that began in May of 2013 on the Sills Ward of Bellville General Hospital in Bellville, Ontario, Canada

View The Presentation Poster from the Conference

 

 

 

 

 

Posted on August 4, 2014

The National Research Council of Canada Viral Testing Laboratory Confirms

MERS Coronavirus Defeated by AsepticSure

Screenshot 2015-06-29 15.16.53

http://www.medizoneint.com/2014/08/04/mers-coronavirus-defeated-by-asepticsure/

 

 

 

 

 

September 2014

AsepticSure Environmental Safety Report

A report produced by Walsh & Associates, a professional safety services company working in conjunction with the Analytical Services Unit of Queen’s University titled Report for Ozone Hydrogen Peroxide Industrial Hygiene Environmental Monitoring was commissioned.

 

The report, provided to the United States EPA, compared results to the following occupational exposure limits and environmental criteria: the Ontario Regulation respecting Control of Exposure to Biological or Chemical Agents (O. Reg. 833) TimeWeighted Average (TWA), ShortTerm Exposure Limit (STEL), and Excursion Limit; the U.S. Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit TWA (PELTWA); the American Conference of Governmental Industrial Hygienists (ACGIH®) Threshold Limit Value TWA (TLV®TWA) and Excursion Limits; the Ontario Ambient Air Quality Criteria (AAQC); Health Canada’s published Lowest Observed Adverse Effect Level (LOAEL); and the U.S. Environmental Protection Agency (EPA) National Ambient Air Quality Standards (NAAQS).

The Report confirmed that the moment the door to the AsepticSure disinfected room was opened following the disinfection process the room was safe and immediately available for occupancy.

 

 

 

 

 

Victoria June 2015

Canadian Infection Prevention and Control Conference

(IPAC-2015)

Queen’s University Professor Emeritus Dick Zoutman, MD, FRCPC by Poster Presentation reported on a C.difficile outbreak that began late November of 2014 on an acute care in-patient ward at Trenton Memorial Hospital, Ontario, Canada

http://www.medizoneint.com/2015/06/18/ipac-poster-victoria-tmh-and-asepticsure-c-difficile/

Key Findings:

  • 4 infected patients on the 25-bed ward with one mortality
  • The outbreak was immediately contained following AsepticSure
  • The ward remained C.difficile free to the conference date
  • A time and cost comparison between conventional isolation room cleaning practices and AsepticSure found a time savings of 2 hours and 20 minutes over the four rooms in AsepticSure’s favor. Supply costs per room for AsepticSure were $3 per room, $7 for the manual method.

 

 

The Unique Superiority of AsepticSure® Disinfection

Facts and Conclusion

*          Using any other conventional double cleaning practices or disinfection technology it is simply not possible to achieve even a 3-log (99.9%) bactericidal and virucidal kill throughout the entire room. AsepticSure achieves > 6-log (> 99.9999%) kill of all pathogens, a thousand times more than 3-log.

*          Why is it necessary to achieve this absolute level of disinfection? Because in laboratory we have proven that following a 3-log, 99.9% kill, the remaining 0.1% of bacteria regenerates to full strength again in five days or less. This explains a major causative factor for the on-going HAI problem in health care facilities. Current practices simply do not eliminate all of the infective pathogens and they then regenerate, providing a reservoir capable of infecting future staff and patients.

 

*          Recent time correlation studies demonstrated that isolation cleaning of 4 patient rooms with AsepticSure actually saved 2 hours and 20 minutes over conventional isolation room cleaning practices.

 

– A BETTER BOTTOM LINE ALL AROUND –

AsepticSure®